The invention relates to identification of regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Feng, Ruoyu
Bourdoux, Andre
Sahli, Hichem
Pollin, Sofie
Abrégé
A method is provided for indoor multipath ghosts recognition for a multiple-input-multiple-output radar with collocated antennas. The method includes the step of generating a two-dimensional Range-Doppler map for N number of consecutive radar data frames. The method further includes the step of applying a temporal clustering algorithm to the N number of consecutive radar data frames. Moreover, the method includes the step of applying a linear pattern extraction algorithm on the two-dimensional Range-Doppler map. In this context, the two-dimensional Range-Doppler map comprises detections from at least one target, at least one first-order ghost, and at least one second-order ghost with respect to one wall reflector.
G06V 20/00 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène
G01S 13/72 - Systèmes radar de poursuite; Systèmes analogues pour la poursuite en deux dimensions, p.ex. combinaison de la poursuite en angle et de celle en distance, radar de poursuite pendant l'exploration
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
G06T 7/277 - Analyse du mouvement impliquant des approches stochastiques, p.ex. utilisant des filtres de Kalman
The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions, such as wounds. The invention provides topical plasters and wound healing compositions. Specifically, the invention provides hydrogels compositions of glycyrrhizinic acid analogues. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
4.
AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER
The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The disclosure relates to the field of the human gut microbiome, more particularly, to its effect on health and disease. Provided herein are means and methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.
The invention is situated in the field of cancer treatment. In particular it relates to treatments comprising combining an inhibitor of the pyrimidinergic receptor P2Y6 and an immune checkpoint inhibitor. Further in particular, the treatment is of benefit for cancers poorly responding to immune checkpoint inhibitor therapy.
The present methods and systems generally relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides an artificial intelligence algorithm which can identify aggregation prone regions, particularly amyloid sequences in a protein.
A61K 31/4535 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p.ex. pizotifène
A61K 31/473 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. acridines, phénantridines
A61P 31/14 - Antiviraux pour le traitement des virus ARN
The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A61P 31/14 - Antiviraux pour le traitement des virus ARN
10.
Means and Methods to Improve Yeast Fermentation Efficiency
The invention relates to the field of microbiology, more particularly to fermentation technology. Yeast fermentation, particularly production of bio-based compounds starting from second generation carbon sources is often hampered by the presence of inhibitory chemicals. This application provides means and methods to overcome the negative effect of fermentation inhibitors, more particularly by providing chimeric genes and yeast strains comprising them that are tolerant to these inhibitors.
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
C12N 1/22 - Procédés utilisant de la cellulose ou ses hydrolysats ou milieux de culture en contenant
C12P 7/10 - Ethanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Van Roy, Willem
Liu, Chengxun
De Moor, Tinne
Abrégé
An electric field gradient focusing device is provided that includes: (i) a fluidic channel having an inlet and an outlet for a fluid, (ii) a first actuator configured to induce a fluid flow in the fluidic channel from the inlet to the outlet via AC electroosmosis, and (iii) a second actuator configured to generate a DC electric field gradient along at least part of the fluidic channel.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
UNIVERSITEIT HASSELT (Belgique)
Inventeur(s)
Kuang, Yinghuan
Aernouts, Tom
Song, Wenya
Lammar, Stijn
Abrégé
A method for forming an intermediate structure in the formation of an optoelectronic device in provided. The method includes: a) obtaining a stack of layers over a substrate holder in a sputtering chamber, the stack of layers comprising an active layer comprising an active material having a perovskite crystal structure, an n-type semiconducting layer comprising a fullerene over the active layer, and an energy alignment layer comprising a lithium halide, a magnesium halide Al2O3 or a metal fluoride on, and in contact with, the n-type semiconducting layer, wherein the energy alignment layer comprises an exposed top surface, and b) sputtering an n-type semiconducting metal oxide layer on the exposed top surface of the energy alignment layer, wherein said sputtering is performed at a sputtering power density of at most 1 W·cm-2 and at a temperature of the stack of layers of at most 100° C.
H01G 9/00 - Condensateurs électrolytiques, redresseurs électrolytiques, détecteurs électrolytiques, dispositifs de commutation électrolytiques, dispositifs électrolytiques photosensibles ou sensibles à la température; Procédés pour leur fabrication
H10K 71/16 - Dépôt d'une matière active organique en utilisant un dépôt physique en phase vapeur [PVD], p. ex. un dépôt sous vide ou une pulvérisation cathodique
H10K 30/40 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant une structure p-i-n, ayant p. ex. un absorbeur pérovskite entre des couches de transport de charge de type p et de type n
H10K 30/30 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des hétérojonctions de masse, p. ex. des réseaux interpénétrés de domaines de matériaux donneurs et accepteurs
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Liu, Chengxun
Dalben Madeira Campos, Camila
Rottenberg, Xavier
Abrégé
Embodiments for sorting particles are provided that include a microfluidic channel configured to receive a microfluidic flow that comprises a plurality of particles having different characteristics, the microfluidic channel having a plurality of output flow channels, a first detector configured to detect the location of the particles, a plurality of actuators located along the direction of the microfluidic flow and defining a sorting electrode arrangement. The microfluidic device further comprises a controller configured to receive signals from the first detector and to provide force field profiles for each of the plurality of particles, wherein each force field profile comprises a plurality of deflection force settings along the direction of the microfluidic flow. The controller individually addresses the plurality of actuators to generate a plurality of actuation inducing fields along the direction of the microfluidic flow to generate the deflection force settings in the force field profiles.
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Huang, Xiaohua
Ballini, Marco
Abrégé
An input circuitry for receiving an analog input signal comprises: an input transistor configured to receive the analog input signal on a gate terminal of the input transistor wherein the input transistor is connected to a digital component providing a digital signal, and wherein the input transistor is configured to receive the digital signal on a bulk terminal of the input transistor; wherein the input transistor is configured to provide an output current based on the analog input signal and the digital signal, such that the input transistor provides digital-to-analog conversion of the digital signal received on the bulk terminal.
H03M 1/68 - Convertisseurs numériques/analogiques à conversions de sensibilités différentes, c. à d. qu'une conversion se rapportant aux bits les plus significatifs et une autre aux bits les moins significatifs
15.
MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL AGGREGATION
The present invention provides non-natural molecules which comprise a peptide part able to stop the amyloid aggregation which is fused to a moiety which stimulates the proteasomal degradation pathway in the cell. Non-natural molecules of the invention are useful to treat human and veterinary pathological aggregation disorders.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Described are methods of analyzing cell free DNA based on combining analysis of cfDNA methylation with analysis of the cfDNA nucleosome footprint and/or with analysis of cfDNA copy number alteration. The diagnostic performance of these methods, in particular relating to early or earlier stage diseases or disorders, is increased compared to the diagnostic performance of the individual cfDNA analysis methods.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Heilmann, Martin
Zhao, Ming
Collaert, Nadine
Parvais, Bertrand
Yadav, Sachin
Abrégé
A method for manufacturing a semiconductor structure is provided. The method includes a III-V semiconductor device in a first region of a base substrate and a further device in a second region of the base substrate. The method includes: (a) obtaining a base substrate comprising the first region and the second region, different from the first region; (b) providing a buffer layer over a surface of the base substrate at least in the first region, wherein the buffer layer comprises at least one monolayer of a first two-dimensional layered crystal material; (c) forming, over the buffer layer in the first region, and not in the second region, a III-V semiconductor material; and (d) forming, in the second region, at least part of the further device. A semiconductor structure is also provided.
H01L 21/8258 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun avec une division ultérieure du substrat en plusieurs dispositifs individuels pour produire des dispositifs, p.ex. des circuits intégrés, consistant chacun en une pluralité de composants le substrat étant un semi-conducteur, en utilisant une combinaison de technologies couvertes par les groupes , , ou
H01L 27/06 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant un corps semi-conducteur comprenant une pluralité de composants individuels dans une configuration non répétitive
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
El Soussi, Mohieddine
Aishajiang, Abuding
Abrégé
A system is provided for performing secure key exchange between a plurality of nodes of a communication network. The system comprises a master node and at least two slave nodes. In this context, the master node is configured to authenticate the at least two slave nodes with a pair-wise authentication key corresponding to each pair of master node and slave nodes. The master node is further configured to generate a group authentication key common to the plurality of nodes. Furthermore, the master node is configured to encrypt the group authentication key with the pair-wise authentication key for each respective pair of master node and slave nodes, thereby generating a respective encrypted group authentication key. Moreover, the master node is configured to communicate the encrypted group authentication key to the respective slave nodes.
The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Current application relates to the field of neurodegenerative diseases. More specifically, the present invention relates to screening methods to identify compounds that can reduce the production of amyloidogenic Amyloid beta fragments. Said compounds can be used in treatments of for example Alzheimer's disease.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Liang, Boshen
Wysocka, Dominika
Cheyns, David
Abrégé
The present disclosure relates to a method for transferring a target layer to a substrate. The method includes providing a stack by forming a first transfer layer over a first substrate, forming a second transfer layer on the first transfer layer, the second transfer layer being water-soluble, and forming the target layer on the second transfer layer, such that the stack has a top surface. The method also includes bonding the top surface of the stack to a second substrate, separating the first transfer layer from the second transfer layer, and dissolving the second transfer layer in water.
B32B 43/00 - Opérations spécialement adaptées aux produits stratifiés et non prévues ailleurs, p.ex. réparation; Appareils pour ces opérations
B81C 1/00 - Fabrication ou traitement de dispositifs ou de systèmes dans ou sur un substrat
B32B 37/24 - Procédés ou dispositifs pour la stratification, p.ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par les propriétés des couches avec au moins une couche qui ne présente pas de cohésion avant la stratification, p.ex. constituée de matériau granulaire projeté sur un substrat
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Lorusso, Gian Francesco
Saib, Mohamed
Moussa, Alain
Charley, Anne-Laure
De Simone, Danilo
Severi, Joren
Abrégé
The present disclosure relates to the determination of a pattern height of a pattern, which has been produced with extreme ultraviolet (EUV) lithography in a resist film. The determination is performed by using an electron beam (e-beam) system, in particular, by using a scanning electron microscope (SEM). In this respect, the disclosure provides a device for determining the pattern height, wherein the device comprising a processor. The processor is configured to obtain a SEM image of the pattern from an SEM. Further, the processor is configured to determine a contrast value related to the pattern based on the obtained SEM image. Subsequently, the processor is configured to determine the pattern height based on calibration data and the determined contrast value.
The present invention in general relates to the field of antibody profiling in spondyloarthritis. In particular, the inventors found that antibody levels against selected peptides are raised in spondylarthritis patients, and herein provide a diagnostic method and kit comprising such peptides for use in the diagnosis of spondyloarthritis.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
24.
Predicting Chronic Allograft Injury Through Age-Related DNA Methylation
The present invention relates to biomarkers for predicting the risk of developing chronic allograft injury in a patient, and means and methods for (post-transplant) preservation of allografts and transplantation organs. In particular, a method to predict the risk of developing chronic allograft injury in a patient is presented based on age-related increase of methylation of CpGs. In particular, the allograft is a kidney.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Disclosed herein are yeast strains and derivatives thereof, as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast strains and compositions. In particular, the yeast strains produce lower glycerol and higher ethanol, and have a higher temperature tolerance and higher fermentation rate than strains and products currently used in ethanol production processes.
C12N 11/10 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique le support étant un hydrate de carbone
C12P 7/06 - Ethanol en tant que produit chimique et non en tant que boisson alcoolique
C12P 7/10 - Ethanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
C12P 7/14 - Fermentation en plusieurs étapes; Fermentation avec différents types de micro-organismes ou avec réemploi de micro-organismes
The present invention relates to the field of neurological diseases, particularly to neurodegenerative diseases caused by dipeptide repeat toxicity. The invention provides genetic and chemical inhibitors of the protein kinase NEK6 to treat amyotrophic lateral sclerosis and frontotemporal dementia.
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/235 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
The present invention relates to binding agents specific for the cystic fibrosis transmembrane conductance regulator (CFTR), which increase its thermal stability to provide for potent therapeutics. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal novel binding sites on the nucleotide-binding domain 1 of CFTR, which allow to rescue pathogenic mutant F508del CFTR from proteasomal degradation. The binding agents are therefore considered suitable in treatment of cystic fibrosis. Finally, also crystalline structures demonstrating binding interfaces, and computer-assisted methods for selecting molecules able to stabilize CFTR are described.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Katholieke Universiteit Leuven, K.U. Leuven R & D (Belgique)
Life Sciences Research Partners VZW (Belgique)
Inventeur(s)
Lambrechts, Diether
Thienpont, Bernard
Abrégé
The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detecting this methylation pattern is a surrogate marker for tumor hypoxia. This can be used to adapt therapy as well.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
29.
METHODS AND MATERIALS FOR TREATING GLYCOSYLATION DISORDERS
This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP)—sugars to treat a mammal (e.g., a human) having a CDG are provided.
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
30.
CD8+ T-CELLS LACKING PLEXINS AND THEIR APPLICATION IN CANCER TREATMENT
The invention relates to field of cancer therapy. In particular, it relates to (populations of) isolated CD8+ T-cells substantially lacking functional plexin-A2 and/or plexin-A4. Such cells can be employed in e.g. adoptive cell transfer to treat a tumor or cancer.
A miniaturized, automated method for controlled printing of large arrays of nano- to femtoliter droplets by actively transporting mother droplets over hydrophilic-in-hydrophobic (“HIH”) micropatches. The technology uses single or double-plate devices where mother droplets can be actuated and HIH micropatches on one or both plates of the device where the droplets are printed. Due to the selective wettability of the hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over the arrays. The parent droplets are moved by various droplet actuation principles. Also, a method using two plates placed one top another while being separated by a spacer. One plate is dedicated to confirming and guiding parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains HIH arrays for printing of the droplets. When the parent droplet guidance plate is rotated over the plate dedicated to printing of nano- to femtoliter droplets, the droplets are dispensed inside the HIH array utilizing their selective wettability. The methods allow the parent droplets to move over the HIH arrays many times, providing advantages for performing bio-assays or miniaturized materials synthesis in nano- to femtoliter sized droplets. With controlled evaporation of the dispensed droplets of solution, large arrays of printed material can be generated in seconds. The methods provide a nano- to femtoliter droplet printing technique for a wide variety of applications, e.g., protein- or cell-based bio-assays or printing of crystalline structures, suspensions of nanoparticles or microelectronic components.
The present invention relates to the field of biochemistry, particularly to the field of yeast fermentations and yeast biomass production, more particularly to modulation of oxidative respiration in yeast. In this application it is disclosed that increasing the respiratory activity in yeast cells reduces the lag phase when switching said yeast cells from glucose to other nutrients. Additionally, a new mutant yeast allele was found that significantly reduces the lag time. The means and methods described herein solve the problem of microbial growth arrest during industrial fermentations when yeasts have to switch to other nutrient sources and provide solutions for the troublesome yeast biomass production.
C07K 14/395 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
C12N 1/18 - Levure de boulangerie; Levure de bière
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
33.
Method and system for indoor multipath ghosts recognition
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Feng, Ruoyu
Bourdoux, Andre
Sahli, Hichem
Pollin, Sofie
Abrégé
A method is provided for indoor multipath ghosts recognition for a multiple-input-multiple-output radar with collocated antennas. The method includes the step of generating a two-dimensional Range-Doppler map for N number of consecutive radar data frames. The method further includes the step of applying a temporal clustering algorithm to the N number of consecutive radar data frames. Moreover, the method includes the step of applying a linear pattern extraction algorithm on the two-dimensional Range-Doppler map. In this context, the two-dimensional Range-Doppler map comprises detections from at least one target, at least one first-order ghost, and at least one second-order ghost with respect to one wall reflector.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G01S 13/72 - Systèmes radar de poursuite; Systèmes analogues pour la poursuite en deux dimensions, p.ex. combinaison de la poursuite en angle et de celle en distance, radar de poursuite pendant l'exploration
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
G06T 7/277 - Analyse du mouvement impliquant des approches stochastiques, p.ex. utilisant des filtres de Kalman
G06V 20/00 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène
34.
System and method for generating a mask for object instances in an image
A system for generating a mask for object instances in an image is provided. The system includes a first module comprising a trained neural network and configured to input the image to the neural network, wherein the neural network is configured to generate: pixel offset vectors for the pixels of the object instance configured to point towards a unique center of an object instance, the pixel offset vectors thereby forming a cluster with a cluster distribution, and for each object instance an estimate of said cluster distribution defining a margin for determining which pixels belong to the object instance. A method for training a neural network map to be used for generating a mask for object instances in an image is also provided.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p.ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersections; Analyse de connectivité, p.ex. de composantes connectées
G06V 10/762 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant le regroupement, p.ex. de visages similaires sur les réseaux sociaux
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 20/58 - Reconnaissance d’objets en mouvement ou d’obstacles, p.ex. véhicules ou piétons; Reconnaissance des objets de la circulation, p.ex. signalisation routière, feux de signalisation ou routes
G06V 20/70 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène Étiquetage du contenu de scène, p.ex. en tirant des représentations syntaxiques ou sémantiques
G06V 40/10 - Corps d’êtres humains ou d’animaux, p.ex. occupants de véhicules automobiles ou piétons; Parties du corps, p.ex. mains
The invention relates to methods of tumor analysis relying on the detection of expression of or of changes in the expression levels of specific retrotransposons. Such methods find application in, amongst other, predicting the response of a tumor to immunotherapy or to immunogenic therapy, and in following up such responses. The expression levels of specific retrotransposons can thus be used in determining which patients are most likely to respond to immunotherapy or immunogenic therapy. Corresponding diagnostic kits are likewise part of the invention.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
36.
Method and apparatus for aligning a probe for scanning probe microscopy to the tip of a pointed sample
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
Paredis, Kristof
Op De Beeck, Jonathan
Fleischmann, Claudia
Vandervorst, Wilfried
Abrégé
Example embodiments relate to methods and apparatuses for aligning a probe for scanning probe microscopy (SPM) to the tip of a pointed sample. One embodiments includes a method for aligning an SPM probe to an apex area of a free-standing tip of a pointed sample. The method includes providing an SPM apparatus that includes the SPM probe; a sample holder; a drive mechanism; and detection, control, and representation tools for acquiring and representing an image of a surface scanned by the SPM probe. The method also includes mounting the sample on the sample holder. Further, the method includes positioning the probe tip of the SPM, determining a 2-dimensional area that includes the pointed sample, performing an SPM acquisition scan, evaluating and acquired image, and placing the SPM probe in a position where it is aligned with an apex area of the free-standing tip of the pointed sample.
The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fimgal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.
C07K 14/40 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures provenant de Candida
The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
39.
PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH ISCHEMIA-INDUCED DNA METHYLATION
The present invention relates to the identification of a specific set of CpG biomarkers for predicting the risk of developing chronic allograft injury in a patient, and means and methods for preservation of allografts and transplantation organs. In particular, a method to predict the risk of developing chronic allograft injury in a patient is presented based on cold-ischemia induced hypermethylation of CpGs as an important driver for downregulation of (promoters of) genes essential for organ preservation. Specifically, a CpG biomarker signature for hypermethylation of renal allograft organs caused by hypoxia and ischemia pre-implantation revealed treatment options of ischemia-associated chronic allograft injury and preservation of donor kidneys.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
40.
CANCER REGRESSION BY INDUCING A REGENERATION-LIKE RESPONSE
The invention relates to the field of oncology, in particular to the field of anti-cancer agents or mechanisms. In particular, activation of a regeneration-like response, such as by activating expression and/or function of YAP and/or TAZ in an organ carrying a tumor or cancer is capable of causing regression of that tumor or cancer.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Krishtab, Mikhail
Armini, Silvia
Abrégé
In a first aspect, the present disclosure relates to a method for forming a patterning mask over a layer to be patterned, the method comprising: (a) providing a first layer over a substrate, the substrate comprising the layer to be patterned, the first layer being capable to bond with a monolayer comprising a compound comprising a functional group for bonding to the first layer and a removable organic group, (b) bonding the monolayer to the first layer, (c) exposing the monolayer to an energy beam, thereby forming a pattern comprising a first area comprising the compound with the removable organic group and a second area comprising the compound not having the removable organic group, and (d) selectively depositing an amorphous carbon layer on top of the first area.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Duckert, Bastien
Braeken, Dries
Fauvart, Maarten
Abrégé
An electrode unit for performing electroporation of a biological cell is provided, including at least one electrode which can contact a cell. A stimulation unit and an impedance measurement device are connected to the cell, respectively to provide signals to provide cell electroporation and to measure the impedance of the electrode in contact with the cell. Further, a memory stores a predetermined value of an impedance parameter of the biological cell, and it is arranged to be readable by a comparing element. The comparing element is configured to compare the value stored in the memory with a value measured with the impedance measurement device, and to produce an adjustment signal to the stimulation unit, forming a feedback loop. The unit is further configured to apply a further electrical signal for providing electroporation of the cell upon receiving the adjustment signal from the comparing element.
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
43.
MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL AGGREGATION
The present invention provides non-natural molecules which comprise a peptide part able to stop the amyloid aggregation which is fused to a moiety which stimulates the proteasomal degradation pathway in the cell. Non-natural molecules of the invention are useful to treat human and veterinary pathological aggregation disorders.
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 2/00 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
45.
Method and device for generating (quasi-) periodic interference patterns
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
Verellen, Niels
Kouznetsov, Dmitry
Van Dorpe, Pol
Abrégé
Example embodiments relate to methods and devices for generating (quasi-) periodic interference patterns. One embodiment includes a method for generating an interference pattern using multi-beam interference of electromagnetic radiation. The method includes computing a set of grid points in a complex plane representing a grid with a desired symmetry. The method also includes selecting a radius of a virtual circle. Additionally, the method includes selecting a set of grid points in the complex plane that lies on the virtual circle centered around a virtual center point. Further, the method includes associating an argument of each grid point of the selected set of grid points in the complex plane with a propagation direction of plane waves or quasi plane waves or parallel wave fronts. In addition, the method includes obtaining the interference pattern that is a superposition of the plane waves or quasi plane waves or parallel wave fronts.
G01J 9/02 - Mesure du déphasage des rayons lumineux; Recherche du degré de cohérence; Mesure de la longueur d'onde des rayons lumineux par des méthodes interférométriques
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Vereecken, Philippe
Chen, Xubin
Mees, Maarten
Abrégé
A solid nanocomposite electrolyte material comprising a mesoporous dielectric material comprising a plurality of interconnected pores and an electrolyte layer covering inner surfaces of the mesoporous dielectric material. The electrolyte layer comprises: a first layer comprising a first dipolar compound or a first ionic compound, the first dipolar or ionic compound comprising a first pole of a first polarity and a second pole of a second polarity opposite to the first polarity, wherein the first layer is adsorbed on the inner surfaces with the first pole facing the inner surfaces; and a second layer covering the first layer, the second layer comprising a second ionic compound or a salt comprising first ions of the first polarity and second ions of the second polarity, wherein the first ions of the ionic compound or salt are bound to the first layer.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.
A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Liu, Chengxun
Stassen, Andim
Set, Ying Ting
Abrégé
A method for continuously separating components from a sample includes providing a field-flow fractionation device including: a channel coupled to a flow generator for translocating the sample components along the channel in a first direction, an actuator for translocating the sample components in a second direction, at an angle with the first direction, and an array of electrodes electrically or capacitively connected to an AC power source, operating the actuator so as to translocate the sample components in a second direction at an angle with the first direction, operating the AC power source so as to generate an AC electric field between adjacent rows, and operating the flow generator, collecting sample components from the sample outlets.
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p.ex. la chromatographie
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
Katholieke Universiteit Leuven, KU LEUVEN R & D (Belgique)
Inventeur(s)
Pitillas Martinez, Andrea Itziar
Put, Brecht
Vereecken, Philippe
Abrégé
A method for coating a conductive polymer onto a cathode-active material for an ion insertion-type electrode comprises: providing an at least partially oxidized cathode-active material having an intrinsic electrode potential, and contacting a precursor of the conductive polymer with the at least partially oxidized cathode-active material. The precursor has a polymerization reduction potential that is lower than the intrinsic electrode potential of the at least partially oxidized cathode-active material, thereby electrochemically polymerizing the precursor onto the cathode-active material.
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/583 - Matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p.ex. LiMn2O4 ou LiMn2OxFy
H01M 10/36 - Accumulateurs non prévus dans les groupes
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 4/60 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés organiques
H01M 10/0568 - Matériaux liquides caracterisés par les solutés
51.
Porous solid materials and methods for fabrication
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
Zankowski, Stanislaw Piotr
Vereecken, Philippe M.
Abrégé
3, a predetermined porosity ranging between 65% and 90% and an electrical conductivity higher than 2000 S/cm. Methods for the fabrication of such porous solid materials and devices including such porous solid material are also disclosed.
C25D 1/08 - Articles perforés ou foraminés, p.ex. tamis
H01B 1/02 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement de métaux ou d'alliages
H01B 5/00 - Conducteurs ou corps conducteurs non isolés caractérisés par la forme
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
52.
Method for forming a bioFET sensor including semiconductor fin or nanowire
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Martens, Koen
Santermans, Sybren
Hellings, Geert
Barge, David
Abrégé
A method for forming a sensor is provided. The method includes: providing an active region comprising a channel having: a length, and a periphery consisting of one or more surfaces having said length, said periphery comprising a first part and a second part, each part having said length, the first part representing from 10 to 75% of the area of the periphery and the second part representing from 25 to 90% of the area of the periphery; providing a first dielectric structure on the entire first part, the first dielectric structure having a maximal equivalent oxide thickness; and providing a second dielectric structure on the entire second part, the second dielectric structure having a minimal equivalent oxide thickness larger than the maximal equivalent oxide thickness of the first dielectric structure.
In general, present invention concerns an integrated wood-to-xylochemicals biorefinery, enabling production of renewable phenol, phenolic oligomers, propylene, and carbohydrate pulp from lignocellulosic biomass.
C07C 37/50 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone d'un cycle aromatique à six chaînons par des réactions diminuant le nombre d'atomes de carbone
B01J 23/40 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe des métaux nobles des métaux du groupe du platine
KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R & D (Belgique)
Inventeur(s)
Mazzone, Massimiliano
Henze, Anne-Theres
Abrégé
Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.
The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.
The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions, such as wounds. The invention provides topical plasters and wound healing compositions. Specifically, the invention provides hydrogels compositions of glycyrrhizinic acid analogues. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
58.
TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH RXR ANTAGONISTS
The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of retinoid X receptor antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of CD36 antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of CD36 antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
The invention relates to the field of tumor disease stratification, in particular melanoma disease stratification. In particular it relates to the methods for tumor analysis, such as for determining tumor cell heterogeneity during treatment. These methods are helpful in selecting or optimizing tumor therapy, or in predicting responses to tumor therapy. The invention further relates to methods for screening for cytotoxic or cytostatic compounds targeting one or more of the heterogeneous tumor cell populations occurring such as during therapy, such as during the minimal residual disease phase.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Van Sieleghem, Edward
Abrégé
Example embodiments relate to single-photon avalanche diode detector (SPAD) arrays. One embodiment includes a SPAD array that includes a silicon substrate, a plurality of primary electrodes, and a plurality of secondary electrodes. Each of the primary electrodes includes a semiconductor material of a first doping type, extends in the silicon substrate in a first direction, and has a rotationally symmetric cross-section in a first plane perpendicular to the first direction. The plurality of secondary electrodes includes a semiconductor material of a second doping type and extends parallel to the primary electrodes in the silicon substrate. Further, the silicon substrate includes a doped upper field redistribution layer, a doped lower field redistribution layer, and a doped depletion layer arranged between the upper field redistribution layer and the lower field redistribution layer. A cross-section of each primary electrode is surrounding by one or more cross-sections of at least one neighboring secondary electrode.
H01L 27/144 - Dispositifs commandés par rayonnement
H01L 31/107 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par une seule barrière de potentiel ou de surface la barrière de potentiel fonctionnant en régime d'avalanche, p.ex. photodiode à avalanche
KATHOLIEKE UNIVERSITEIT LEUVEN KU LEUVEN (Belgique)
STICHTING IMEC NEDERLAND (Pays‑Bas)
Inventeur(s)
Lin, Qiuyang
Xu, Jiawei
Song, Shuang
Van Helleputte, Nick
Tavernier, Filip
Abrégé
A light-to-digital converter (2) comprises a light-to-current converter (10); a current integrator (4) with an integrator output (30) resettable to a baseline level; and a counter (18) with a digital output (26), wherein the light-to-current converter (10) is switchably connectable as a positive integration input to the current integrator (4), for, during a light-collecting phase (404-406), integrating a current from the light-to-current converter (10), the integrator output (30) starting from the baseline value and ending at a value to be digitized; a reference current source (14) is switchably connectable as a negative integration input to the current integrator (4), for, during a counting phase (406-408) subsequent to the light-collecting phase (404-406), integrating a reference current from the reference current source (14), the integrator output (30) starting from the value to be digitized and ending at the baseline value, the time spent integrating the reference current corresponding to the value to be digitized; and the counter (18) is configured for measuring the time.
A miniaturized, automated method for controlled printing of large arrays of nano- to femtoliter droplets by actively transporting mother droplets over hydrophilic-in-hydrophobic (“HIH”) micropatches. The technology uses single or double-plate devices where mother droplets can be actuated and HIH micropatches on one or both plates of the device where the droplets are printed. Due to the selective wettability of the hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over the arrays. The parent droplets are moved by various droplet actuation principles. Also, a method using two plates placed one top another while being separated by a spacer. One plate is dedicated to confirming and guiding parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains HIH arrays for printing of the droplets. When the parent droplet guidance plate is rotated over the plate dedicated to printing of nano- to femtoliter droplets, the droplets are dispensed inside the HIH array utilizing their selective wettability. The methods allow the parent droplets to move over the HIH arrays many times, providing advantages for performing bio-assays or miniaturized materials synthesis in nano- to femtoliter sized droplets. With controlled evaporation of the dispensed droplets of solution, large arrays of printed material can be generated in seconds. The methods provide a nano- to femtoliter droplet printing technique for a wide variety of applications, e.g., protein- or cell-based bio-assays or printing of crystalline structures, suspensions of nanoparticles or microelectronic components.
The present invention relates to the field of probiotics, more particularly to the probiotic yeast Saccharomyces boulardii. Even more particularly the present invention relates to enhanced probiotic potency of S. boulardii. The present invention provides mutant alleles useful to develop yeast strains with enhanced production of acetic acid. In addition, the invention also relates to the use of such yeast strains for the production of dietary supplements or pharmaceutical compositions to improve gastrointestinal comfort.
C12N 1/18 - Levure de boulangerie; Levure de bière
C07K 14/395 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
A61K 36/064 - Saccharomycetales, p.ex. levure de boulanger
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Li, Yuqian
Vanmeerbeeck, Geert
Dusa, Alexandra
Abrégé
Disclosed herein are cell differentiating systems for differentiating cells. The systems comprise an input means for receiving a reconstructed image of a cell based on a holographic image of the cell in suspension, and a cell recognition means for determining cell characterization features from the reconstructed image of the cell for characterization of the cell. The cell recognition means thereby is configured for determining, as cell recognition features, image moments.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G01N 15/14 - Recherche par des moyens électro-optiques
G06K 9/52 - Extraction d'éléments ou de caractéristiques de l'image en déduisant des propriétés mathématiques ou géométriques de l'image complète
G01N 15/10 - Recherche de particules individuelles
The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Gallagher, Emily
Franke, Joern-Holger
Pollentier, Ivan
Timmermans, Marina
Mariano Juste, Marina
Abrégé
The present disclosure relates to a lithography scanner including: a light source configured to emit extreme ultra-violet (EUV) light; a pellicle including an EUV transmissive membrane that is configured to scatter the EUV light into an elliptical scattering pattern having a first major axis; a reticle configured to reflect the scattered EUV light through the pellicle; and an imaging system configured to project a portion of the reflected light that enters an acceptance cone of the imaging system onto a target wafer, wherein a cross section of the acceptance cone has a second major axis, and wherein the pellicle is arranged such that the first major axis is oriented at an angle relative to the second major axis.
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
H05G 2/00 - Appareils ou procédés spécialement adaptés à la production de rayons X, n'utilisant pas de tubes à rayons X, p.ex. utilisant la génération d'un plasma
D01F 9/12 - Filaments de carbone; Appareils spécialement adaptés à leur fabrication
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Mariano Juste, Marina
Timmermans, Marina
Pollentier, Ivan
Huyghebaert, Cedric
Gallagher, Emily
Abrégé
A method for protecting a photomask comprises: (i) providing the photomask, (ii) providing a border, (iii) depositing at least two electrical contacts on the border, (iv) mounting a film comprising carbon nanotubes on the border such that the film comprises a free-standing part, wherein after the mounting and depositing steps, the electrical contacts are in contact with the film, (v) inducing a current through the free-standing part of the film by biasing at least one pair of the electrical contacts, and (vi) mounting the border on at least one side of the photomask with the free-standing part of the film above the photomask.
G03F 1/64 - Pellicules, p.ex. assemblage de pellicules ayant une membrane sur un cadre de support; Leur préparation caractérisés par les cadres, p.ex. du point de vue de leur structure ou de leur matériau
G03F 1/62 - Pellicules, p.ex. assemblage de pellicules ayant une membrane sur un cadre de support; Leur préparation
G03F 1/40 - Aspects liés à la décharge électrostatique [ESD Electrostatic Discharge], p.ex. revêtements antistatiques ou présence d'une couche métallique conductrice sur la périphérie du substrat du masque
69.
GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION
The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regeneration of skeletal muscle.
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
Garbin, Daniele
Lavizzari, Simone
Abrégé
A neural network circuit for providing a threshold weighted sum of input signals comprises at least two arrays of transistors with programmable threshold voltage, each transistor storing a synaptic weight as a threshold voltage and having a control electrode for receiving an activation input signal. Additionally, for each array of transistors, a reference network associated therewith, which provides a reference signal to be combined with the positive or negative weight current components of the transistors of the associated array, the reference signal having opposite sign compared to the weight current components of the associated array, thereby providing the threshold of the weighted sums of the currents. Further, at least one bitline is configured to receive the combined positive and/or negative current components, each combined with their associated reference signals.
G06N 3/063 - Réalisation physique, c. à d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
G11C 16/26 - Circuits de détection ou de lecture; Circuits de sortie de données
71.
Selective deposition for interdigitated patterns in solar cells
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Xu, Menglei
Bearda, Twan
Sivaramakrishnan Radhakrishnan, Hariharsudan
Poortmans, Jef
Abrégé
Example embodiments relate to selective deposition for interdigitated patterns in solar cells. One embodiment includes a method for creating an interdigitated pattern for a solar cell. The method includes providing a substrate of the solar cell. A surface of the substrate includes one or more exposed regions and one or more regions covered by a patterned first passivation layer stack protected by a hard mask. The method also includes selectively depositing a second passivation layer stack that includes at least a first layer of amorphous silicon (a-Si) on the one or more exposed regions such that the first passivation layer stack and the second passivation layer stack form the interdigitated pattern. Selectively depositing the second passivation layer stack includes adding a sublayer of the first layer on the hard mask, etching the added sublayer on the hard mask, and cleaning a surface of the remaining added sublayer.
H01L 31/0747 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV] caractérisés par au moins une barrière de potentiel ou une barrière de surface les barrières de potentiel étant uniquement du type PN à hétérojonction comprenant uniquement une hétérojonction AIVBIV, p.ex. cellules solaires Si/Ge, SiGe/Si ou Si/SiC comprenant une hétérojonction avec des matériaux cristallins et amorphes, p.ex. cellules solaires avec une couche mince intrinsèque ou HIT®
H01L 31/20 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - les dispositifs ou leurs parties constitutives comprenant un matériau semi-conducteur amorphe
72.
Device for analysis of cells and a method for manufacturing of a device
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Braeken, Dries
Reumers, Veerle
Andrei, Alexandru
Firrincieli, Andrea
Pauwelyn, Thomas
Abrégé
A device for analysis of cells comprises: an integrated circuit arrangement on a substrate; a dielectric layer formed above the integrated circuit arrangement; a microelectrode array layer formed above the dielectric layer, said microelectrode array layer comprising a plurality of individual electrodes, wherein each electrode is connected to the integrated circuit arrangement through a via in the dielectric layer; and wherein a plurality of longitudinal trenches in the dielectric layer and the microelectrode array layer are for stimulating cell growth on a surface of the device
G01N 33/483 - Analyse physique de matériau biologique
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
73.
Microfluidic device for electrically activated passive capillary stop valve
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Barman, Ujjal
Jones, Benjamin
Fiorini, Paolo
Mikaelian, David
Abrégé
A microfluidic device for electrically activating a passive capillary stop valve, an apparatus and method are provided. The microfluidic device includes a first channel for containing a first fluid, and an output channel, wherein the first channel comprises a first interface with the output channel, and the first interface comprises a capillary stop valve characterised in that the microfluidic device also comprises a second channel for containing a second fluid, wherein the second channel comprises a second interface with the output channel, and the first channel and the second channel are electrically isolated from each other, and the first interface and the second interface are arranged relative to each other thereby being configured to activate fluid flow from the first channel into the output channel when a first fluid and a second fluid are present, and an electrical potential difference is applied between the first fluid and the second fluid.
The present invention relates to the field of fermentation, more particularly to ethanol production. Even more particularly the present invention relates to reduced aroma production during fermentation processes. The present invention provides mutant alleles and chimeric genes useful to develop yeast strains to limit acetate ester levels during fermentation. In addition, the invention also relates to the use of such yeast strains as well as of compounds for the production of fermented foods and liquids with reduced acetate ester levels.
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 9/60 - Protéinases provenant de champignons de levure
C12G 3/00 - Préparation d'autres boissons alcoolisées
C07K 14/395 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
C12G 3/02 - Préparation d'autres boissons alcoolisées par fermentation
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
De Wijs, Koen Johannes Hubertus Gerardus
Liu, Chengxun
Abrégé
Disclosed herein are microfluidic actuators for selecting objects in a fluid stream comprising a plurality of objects. In some embodiments, the actuator comprises an object detection means adapted for, upon arrival of an object, identifying whether an object is an object of interest. It further comprises a heater adapted for generating a jet flow for deflecting an object of interest from the fluid stream and a controller for activating the heater as function of the detection of an object of interest using a nucleation signal. The controller is adapted for obtaining temperature information of the heater and for adjusting a nucleation signal for the heater taking into account the obtained temperature information. Also disclosed are microfluidic systems and diagnostic devices comprising the microfluidic actuators of the disclosure, as well as methods of use thereof.
G01N 15/00 - Recherche de caractéristiques de particules; Recherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B01L 7/00 - Appareils de chauffage ou de refroidissement; Dispositifs d'isolation thermique
G01N 15/10 - Recherche de particules individuelles
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
De Strooper, Bart
Chávez Gutiérrez, Lucia
Szaruga, Maria
Abrégé
The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer Aβ peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential γ-secretase processing of APP, to result in reduced amyloidogenic Aβ production, thereby preventing Alzheimer disease.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
77.
Xylose isomerases that confer efficient xylose fermentation capability to yeast
Clostridium cellulosi and others. The invention further relates to fermentation processes wherein the transformed host cells ferment a xylose-containing medium to produce ethanol or other fermentation products.
C12P 5/02 - Préparation des hydrocarbures acycliques
C12P 7/10 - Ethanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Janes, Dustin
Doise, Jan
Abrégé
A method for forming on a substrate a cross-linked layer for directing the self-assembly of a self-assembling material is provided. The method including: (a) providing a structure having the substrate; (b) providing on the substrate a layer of a photo- and thermally cross-linkable substance which, when crosslinked, is suitable for directing the self-assembly of a self-assembling material; (d) photocrosslinking the cross-linkable substance partially; and (d) cross-linking the substance further thermally, thereby forming the cross-linked layer.
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
79.
Vertical takeoff and landing unmanned aerial vehicle
BR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 9/36 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-1, 4 de l'acide N-acétylmuramique avec l'acétylamino-2 déoxy-2-D-glucose, p.ex. lysozyme
C12N 15/56 - Hydrolases (3) agissant sur les composés glycosyliques (3.2), p.ex. amylase, galactosidase, lysozyme
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p.ex. cellulases, lactases
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Mao, Shengping
Sohn, Erik
Rottenberg, Xavier
Liu, Chengxun
Abrégé
At least one embodiment relates to a focusing arrangement for focusing particles or cells in a flow. The arrangement includes at least one channel for guiding the flow. The channel includes (i) at least one particle confinement structure having particle flow boundaries and (ii) at least one acoustic confinement structure having acoustic field boundaries adapted for confining acoustic fields. The acoustic field boundaries may be different from the particle flow boundaries, and the at least one acoustic confinement structure may be arranged with regard to the channel to at least partially confine acoustic fields in the channel.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 29/22 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonores; Visualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet - Détails
G01N 15/14 - Recherche par des moyens électro-optiques
G01N 15/00 - Recherche de caractéristiques de particules; Recherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p.ex. adaptation de la température, irradiation
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Krishtab, Mikhail
Armini, Silvia
Stassen, Ivo
Ameloot, Rob
Abrégé
Example embodiments relate to selective deposition of metal-organic frameworks. One embodiment includes a method of forming a low-k dielectric film selectively on exposed dielectric locations in a substrate. The method includes selectively depositing a metal-containing film, using an area-selective deposition process, on the exposed dielectric locations using one or more deposition cycles. The method also includes providing, at least once, a vapor of at least one organic ligand to the deposited metal-containing film resulting in a gas-phase chemical reaction thereby obtaining a metal-organic framework which is the low-k dielectric film. The low-k dielectric film has gaps on locations where no metal-containing film was deposited.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Pays‑Bas)
Inventeur(s)
Smets, Elena
Rios Velazquez, Emmanuel
Schiavone, Giuseppina
De Raedt, Walter
Van Hoof, Christiaan
Abrégé
Disclosed herein is a system for determining a subject's stress condition. The system includes a stress test unit configured for: receiving features defining the subject and physiological signals sensed from the subject when performing a relaxation and a stressful test task; extracting normalization parameters from the physiological signals; and identifying stress-responsive physiological features. The system also includes a storage unit configured for: storing a plurality of stress models; and storing the subject's features, normalization parameters, and the stress-responsive physiological features. The system also includes a stress detection unit configured for: selecting a stress model from the plurality of stress models based on the subject's features and the stress responsive physiological features; estimating a specific stress condition based on the stress model, stored subject's features, normalization parameters, and physiological signals that apply to the selected stress model; and providing a stress value representative of the subject's stress condition.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
Katholieke Universiteit Leuven, K.U. Leuven R & D (Belgique)
Inventeur(s)
Goodchild, Rose
Grillet, Micheline
Abrégé
The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Adelmann, Hanns Christoph
Philipsen, Vicky
Luong, Kim Vu
Abrégé
Example embodiments relate to extreme ultraviolet absorbing alloys. One example embodiment includes an alloy. The alloy includes one or more first elements selected from: a first list consisting of: Ag, Ni, Co, and Fe; and a second list consisting of: Ru, Rh, Pd, Os, Ir, and Pt. The alloy also includes one or more second elements selected from: the first list, if the one or more first elements are not selected from the first list; and a third list consisting of Sb and Te. An atomic ratio between the one or more first elements and the one or more second elements is between 1:1 and 1:5 if the one or more second elements are selected from the third list and between 1:1 and 1:19 if the one or more second elements are not selected from the third list.
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Chan, Boon Teik
Luong, Kim Vu
Philipsen, Vicky
Altamirano Sanchez, Efrain
Vandersmissen, Kevin
Abrégé
An example method for making a reticle includes providing an assembly. The assembly includes an extreme ultraviolet mirror and a cavity overlaying at least a bottom part of the extreme ultraviolet mirror. The method also includes at least partially filling the cavity with an extreme ultraviolet absorbing structure that includes a metallic material that includes an element selected from Ni, Co, Sb, Ag, In, and Sn, by forming the extreme ultraviolet absorbing structure selectively in the cavity.
G03F 1/24 - Masques en réflexion; Leur préparation
G03F 1/22 - Masques ou masques vierges d'imagerie par rayonnement d'une longueur d'onde de 100 nm ou moins, p.ex. masques pour rayons X, masques en extrême ultra violet [EUV]; Leur préparation
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Gallagher, Emily
Gronheid, Roel
Doise, Jan
Mochi, Iacopo
Abrégé
A mask structure and a method for manufacturing a mask structure for a lithography process is provided. The method includes providing a substrate covered with an absorber layer on a side thereof; providing a patterned layer over the absorber layer, the patterned layer comprising at least one opening; and forming at least one assist mask feature in the at least one opening, wherein the at least one assist mask feature is formed by performing a directed self-assembly (DSA) patterning process comprising providing a BCP material in the at least one opening and inducing phase separation of a BCP material into a first component and a second component, the first component being the at least one assist mask feature and being periodically distributed with respect to the second component.
H01L 21/308 - Traitement chimique ou électrique, p.ex. gravure électrolytique en utilisant des masques
H01L 21/027 - Fabrication de masques sur des corps semi-conducteurs pour traitement photolithographique ultérieur, non prévue dans le groupe ou
G03F 7/11 - Matériaux photosensibles - caractérisés par des détails de structure, p.ex. supports, couches auxiliaires avec des couches de recouvrement ou des couches intermédiaires, p.ex. couches d'ancrage
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
G03F 1/36 - Masques à correction d'effets de proximité; Leur préparation, p.ex. procédés de conception à correction d'effets de proximité [OPC optical proximity correction]
G03F 1/68 - Procédés de préparation non couverts par les groupes
C09D 153/00 - Compositions de revêtement à base de copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carbone; Compositions de revêtement à base de dérivés de tels polymères
89.
Method of propagating magnetic domain wall in magnetic devices
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Vaysset, Adrien
Zografos, Odysseas
Abrégé
The disclosed technology generally relates to magnetic devices, and more particularly to magnetic devices configured to generate a stream of domain walls propagating along an output magnetic bus. In an aspect, a magnetic device includes a magnetic propagation layer, which in turn includes a plurality of magnetic buses. The magnetic buses include at least a first magnetic bus, a second magnetic bus, and an output magnetic bus configured to guide propagating magnetic domain walls. The magnetic propagation layer further comprises a central region in which the magnetic buses converge and are joined together. In another aspect, a method includes providing the magnetic device and generating the stream of domain walls propagating along the output magnetic bus.
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliers; Eléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
G11C 19/08 - Mémoires numériques dans lesquelles l'information est déplacée par échelons, p.ex. registres à décalage utilisant des éléments magnétiques utilisant des couches minces dans une structure plane
G11C 5/06 - Dispositions pour interconnecter électriquement des éléments d'emmagasinage
The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
Katholieke Universiteit Leuven, KU LEUVEN R&D. (Belgique)
Inventeur(s)
Stassen, Ivo
Ameloot, Rob
De Vos, Dirk
Vereecken, Philippe M.
Abrégé
A method of producing a metal-organic framework (MOF) film on a substrate is provided. The method includes providing a substrate having a main surface and forming on the main surface a MOF film using an organometallic compound precursor and at least one organic ligand, wherein each of the organometallic compound precursor and the at least one organic ligand is provided only in the vapour phase.
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
C23C 16/44 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le procédé de revêtement
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Doise, Jan
Abrégé
A method for directing a self-assembly of a block copolymer comprising a first and a second block is provided. The method including: providing a substrate comprising at least one concavity therein, the concavity comprising at least a sidewall and a bottom, the bottom having a preferential wetting affinity for the second block with respect to the first block; grafting a first grafting material onto the sidewall, selectively with respect to the bottom, the first grafting material having a preferential wetting affinity for the first block with respect to the second block; grafting a second grafting material onto the bottom and optionally onto the sidewall, the second grafting material having a preferential wetting affinity towards the first block with respect to the second block; and providing the block copolymer on the substrate, at least within the at least one concavity.
H01L 21/027 - Fabrication de masques sur des corps semi-conducteurs pour traitement photolithographique ultérieur, non prévue dans le groupe ou
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
C30B 25/18 - Croissance d'une couche épitaxiale caractérisée par le substrat
H01L 21/768 - Fixation d'interconnexions servant à conduire le courant entre des composants distincts à l'intérieur du dispositif
B81C 1/00 - Fabrication ou traitement de dispositifs ou de systèmes dans ou sur un substrat
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
H01L 21/033 - Fabrication de masques sur des corps semi-conducteurs pour traitement photolithographique ultérieur, non prévue dans le groupe ou comportant des couches inorganiques
H01L 21/308 - Traitement chimique ou électrique, p.ex. gravure électrolytique en utilisant des masques
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Tait, Jeffrey Gerhart
Gardner, Kira
Gehlhaar, Robert
Qiu, Weiming
Merckx, Tamara
Abrégé
wherein the polar aprotic solvent or mixture of polar aprotic solvents represent between 50 and 95 vol % of the mixture of solvents, wherein the vol % of the mixture of solvents not occupied by polar aprotic solvents is occupied for at least 90 vol %, preferably for 100 vol %, by the one or more linear alcohols, and the one or more acids if present.
C30B 29/00 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme
H01L 29/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails des corps semi-conducteurs ou de leurs électrodes
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
C23C 18/12 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement; Dépôt par contact par décomposition thermique caractérisée par le dépôt sur des matériaux inorganiques, autres que des matériaux métalliques
H01G 9/00 - Condensateurs électrolytiques, redresseurs électrolytiques, détecteurs électrolytiques, dispositifs de commutation électrolytiques, dispositifs électrolytiques photosensibles ou sensibles à la température; Procédés pour leur fabrication
H01L 51/42 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement
94.
MEANS AND METHODS FOR TREATING BACTERIAL INFECTIONS
The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.
Katholieke Universiteit Leuven, KU LEUVEN R&D (Belgique)
Inventeur(s)
Pamula, Venkata Rajesh
Verhelst, Marian
Abrégé
Example embodiments relate to systems and methods for heart rate detection with motion artifact reduction. One embodiment includes an electronic system for heart rate detection. The electronic system includes a random sampling sensor module. The random sampling sensor module includes a first sensor circuit configured to provide nonuniform random samples below a Nyquist rate of a photoplethysmographic signal. The random sample sensor module also includes a second sensor circuit configured to provided nonuniform random samples below a Nyquist rate of a motion signal. The motion signal and the photoplethysmographic signals are sampled with an equivalent pattern. The electronic system also includes a heart rate detection module. The heart rate detection module is configured to calculate a heart rave value based on frequencies corresponding to peak powers of calculated power spectral density value sets corresponding to the photoplethysmographic signals in a frequency range of interest.
The present invention relates to the field of fermentation, more particularly to ethanol production. Even more particularly the present invention relates to reduced aroma production during fermentation processes. The present invention provides mutant alleles and chimeric genes useful to develop yeast strains to limit acetate ester levels during fermentation. In addition, the invention also relates to the use of such yeast strains as well as of compounds for the production of fermented foods and liquids with reduced acetate ester levels.
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C07K 14/395 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
C12G 3/00 - Préparation d'autres boissons alcoolisées
Katholieke Universiteit Leuven, KU LEUVEN R& D (Belgique)
Universiteit Gent (Belgique)
Inventeur(s)
Van Campenhout, Joris
Merckling, Clement
Pantouvaki, Maria Ioanna
Srinivasan, Ashwyn
Kulkova, Irina
Abrégé
An electrically-operated semiconductor laser device and method for forming the laser device are provided. The laser device includes a fin structure to which a waveguide is optically coupled. The waveguide is optically coupled to passive waveguides at either end thereof. The fin structure includes an array of fin elements, each fin element comprising Group III-V materials.
H01S 5/323 - Structure ou forme de la région active; Matériaux pour la région active comprenant des jonctions PN, p.ex. hétérostructures ou doubles hétérostructures dans des composés AIIIBV, p.ex. laser AlGaAs
H01S 5/026 - Composants intégrés monolithiques, p.ex. guides d'ondes, photodétecteurs de surveillance ou dispositifs d'attaque
H01S 5/10 - Structure ou forme du résonateur optique
H01S 5/343 - Structure ou forme de la région active; Matériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p.ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH] dans des composés AIIIBV, p.ex. laser AlGaAs
H01S 5/12 - Structure ou forme du résonateur optique le résonateur ayant une structure périodique, p.ex. dans des lasers à rétroaction répartie [lasers DFB]
H01S 5/02 - Lasers à semi-conducteurs - Détails ou composants structurels non essentiels au fonctionnement laser
H01S 5/30 - Structure ou forme de la région active; Matériaux pour la région active
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Raghavan, Praveen
Zografos, Odysseas
Abrégé
A semiconductor device is disclosed that includes a substrate and at least a first, second, third, and fourth vertical transistor supported by the substrate. Each transistor comprises a vertical channel, a polarity gate electrode forming a polarity gate adapted to act on a first portion of the channel to affect a polarity of the channel, and a control gate electrode forming a control gate adapted to act on a second portion of the channel to control the electrical conductivity of the channel. The polarity gate electrode and the control gate electrode of each one of the transistors extend laterally from their respective gate and in mutually opposite directions, and the transistors are laterally spaced from each other and arranged such that the control gate electrodes of the first and third transistor face each other and the control gate electrodes of the second and fourth transistor face each other.
Katholieke Universiteit Leuven, KU Leuven R&D (Belgique)
Inventeur(s)
Sakhare, Sushil
Huynh Bao, Trong
Perumkunnil, Manu Komalan
Abrégé
A memory cell is disclosed, comprising a static random-access memory, SRAM, bit cell, a first resistive memory element and a second resistive memory element. The first resistive memory element is connected to a first storage node of the SRAM bit cell and a first intermediate node, and the second resistive memory element connected to a second storage node of the SRAM bit cell and a second intermediate node. Each one of the first intermediate node and the second intermediate node is configured to be supplied with a first supply voltage via a first transistor and a second supply voltage via a second transistor, wherein the first transistor and the second transistor are complementary transistors separately controllable by a first word line and a second word line, respectively. Methods for operating such a memory cell are also disclosed.
G11C 14/00 - Mémoires numériques caractérisées par des dispositions de cellules ayant des propriétés de mémoire volatile et non volatile pour sauvegarder l'information en cas de défaillance de l'alimentation
G11C 11/417 - Circuits auxiliaires, p.ex. pour l'adressage, le décodage, la commande, l'écriture, la lecture, la synchronisation ou la réduction de la consommation pour des cellules de mémoire du type à effet de champ
G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliers; Eléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
G11C 11/412 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliers; Eléments d'emmagasinage correspondants utilisant des éléments électriques utilisant des dispositifs à semi-conducteurs utilisant des transistors formant des cellules avec réaction positive, c. à d. des cellules ne nécessitant pas de rafraîchissement ou de régénération de la charge, p.ex. multivibrateur bistable, déclencheur de Schmitt utilisant uniquement des transistors à effet de champ
A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer. One plate is dedicated to confirming and guiding of parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains hydrophilic-in-hydrophobic arrays dedicated to the printing of nano- to femtoliter droplets. When the plate dedicated to parent droplet guiding is rotated over the plate dedicated to printing of nano- to femtoliter droplets, nano- to femtoliter droplets are dispensed inside the hydrophilic-in-hydrophobic array due to their selective wettability. All these proposed methods allow the parent droplets to be moved over the hydrophilic-in-hydrophobic arrays many times, providing unique advantages for performing bio-assays or miniaturized materials synthesis in nano- to femtoliter sized droplets. Upon the controlled evaporation of the dispensed droplets of solution, large arrays of the printed material can be generated on an automated way in seconds of time on a very flexible way. The method disclosed herein provides a distinct nano- to femtoliter droplet printing technique for a wide variety of applications such as protein- or cell-based bio-assays or printing of crystalline structures, suspensions of nanoparticles or components for microelectronics.